KMT2A and acute lymphoblastic leukemia: For infants diagnosed with acute lymphoblastic leukemia (ALL), approximately 60–80% have an MLL rearrangement, which has been identified as a molecular feature associated with a very poor prognosis, with overall survival less than 50% [5, 6].